What are the precautions for ziftomenib-Komzifti?

Ziftomenib - Komzifti is a new drug for the treatment of relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). When using ziftomenib, patients should pay special attention to possible serious side effects and related precautions.

1. Differentiation syndrome is a serious side effect associated withziftomenib treatment that may appear in as little as 3 days after the start of treatment. Symptoms include fever, joint or bone pain, dizziness, shortness of breath, cough, chest pain, rapid weight gain, decreased urine output, and swelling of the hands and feet. If these symptoms occur, you should go to the hospital immediately. In response to differentiation syndrome, doctors may temporarily stop ziftomenib and prescribe corticosteroid drugs to relieve symptoms.

2. Changes in cardiac electrical activity are also matters that must be closely monitored when usingziftomenib. Prolongation of the QT interval may lead to irregular heartbeats, which may be life-threatening in severe cases. During treatment, doctors will monitor the heart's electrical activity through an electrocardiogram and measure potassium and magnesium ion levels in the blood. If patients experience symptoms such as syncope, dizziness, shortness of breath, or irregular heartbeat during treatment, they need to inform their doctor immediately.

3. Patients should inform their doctors about their health conditions before using ziftomenib, including whether they have heart disease (such as long QT syndrome) or abnormal electrolyte levels (such as abnormal potassium and magnesium).

4. Pregnant women or women planning to become pregnant need to be particularly cautious, becauseziftomenib may cause harm to the unborn baby. Before treatment, the doctor will conduct a pregnancy test. Women should take effective contraceptive measures during treatment and within 6 months after stopping the drug. Men with childbearing potential should also take contraceptive measures during the treatment and within 3 months after stopping the drug.

5. For women who are breast-feeding or plan to breast-feed, it is currently unknown whether ziftomenib will pass into breast milk, so they should not breast-feed during treatment and within 2 weeks after the last dose.

6. Patients need to inform their doctors of all other drugs they are taking, including prescription drugs, over-the-counter drugs, vitamins and herbal supplements, becauseziftomenib may interact with other drugs, causing adverse reactions. Make sure you know all the information you need about your medications and keep a medication list so you can always provide it to your doctor.

Reference materials:https://www.drugs.com/komzifti.html